Navigation Links
Shengtai Pharmaceutical, Inc. Comments on China's Recently Approved Health Care Reform Plan

WEIFANG, China, Feb. 5 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today commented on a recently released State Council approved plan to spend a total of 850 billion RMB (USD 123 billion) by 2011 to provide universal primary medical services. Over the next three years, the multi-billion health care plan is aimed at expanding the government-sponsored medical insurance network to provide affordable, basic health care coverage to over 90% of the population. The plan seeks to expand health care services by targeting the country's approximately 900 million farmers, many of whom lack basic medical insurance, to ensure they are covered under the program. Under the plan, each person covered by the program will receive an annual health care subsidy after the 2010 year. In addition, the government will build hospitals and community health clinics to improve medical services in the rural and under-developed areas.

"We believe Shengtai stands to benefit from the government's plan as our pharmaceutical grade glucose is a basic raw material used in medical transfusions, which is also the most common form of medical treatment in China," said Mr. Qingtai Liu, Shengtai Pharmaceutical's CEO. "As the government builds more rural hospitals and community health clinics, we believe there will be an increased demand for glucose as more patients receive transfusions as part of their basic medical services. With our state-of-the-art glucose production facilities, we have the production capacity to meet the anticipated increase in glucose demand. This production expansion, in addition to the recent reorganization of our domestic and international sales department, positions us so we are ready to take advantage of additional market opportunities. Our actions are part of our efforts to provide existing and potential new customers with high-quality products, and a solid platform from which we can grow and maintain our leadership in our business."

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes. It also manufactures and supplies glucose and cornstarch products to the food, beverage and industrial production industries in China. For more information about Shengtai Pharmaceutical, Inc., please visit .

Forward-looking Statements

Certain statements made in this news release, may contain forward-looking statements concerning the Company's business and products. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, the Company's planned capacity expansion and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large-scale implementation of the Company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

    For more information, please contact:

    Shengtai Pharmaceutical, Inc.
     Ms. Yiru Melody Shi
     Chief Financial Officer
     Tel:   +1-949-468-7078

    Grayling Global
     Eddie Cheung
     Investor Relations
     Tel:   +1-646-284-9414

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
2. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
6. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
7. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
8. Shengtai Pharmaceutical Expands International Sales Program
9. Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference
10. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
11. BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology: